Literature DB >> 15589797

Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.

Gustavo Adolfo Sierra Romero1, Maria de la Glória Orge Orge, Marcus Vinitius de Farias Guerra, Marcilene Gomes Paes, Vanize de Oliveira Macêdo, Edgar M de Carvalho.   

Abstract

The antibody response against Leishmania (Leishmania) amazonensis crude antigen was measured through the indirect immunofluorescent assay (IFA) and the immunoenzymatic assay (ELISA) in 114 patients with cutaneous leishmaniasis (CL) in Brazil. Fifty-four patients were infected by Leishmania (Viannia) braziliensis, and 60 patients had L. (V.) guyanensis infection. Patients were comparable by age, sex, disease duration and the Montenegro skin test diameter. L. (V.) braziliensis-infected patients showed significant lower number of ulcerated lesions, greater ulcerated area and higher proportion of lymph node enlargement. Sensitivity of IFA was 79.6% (95% CI 66.1-88.9) and 71.7% (95% CI 58.4-82.2) for L. (V.) braziliensis and L. (V.) guyanensis-infected patients, respectively (P=0.324). Sensitivity of ELISA was 98.2% (95% CI 88.8-99.9) and 85.0% (95% CI 72.9-92.5) for L. (V.) braziliensis and L. (V.) guyanensis-infected patients, respectively (P=0.018). Significant differences were observed in the magnitude of the antibody response before treatment with higher levels detected in L. (V.) braziliensis-infected patients by both serologic techniques. Eighty-four patients had serologic evaluations before and 12 weeks after treatment with meglumine antimoniate, 20 mg/kg/day for 20 days. Significant lower optic density values were observed after treatment with both species independent of cure or failure. Our data showed that L. (V.) braziliensis induces a higher antibody response against L. (L.) amazonensis antigens than L. (V.) guyanensis and that down-modulation of the antibody response occurs shortly during disease evolution after treatment. Moreover the data support the use of ELISA as a better tool for detection of antibodies in CL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15589797     DOI: 10.1016/j.actatropica.2004.09.005

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  18 in total

1.  Mucosal Leishmania infantum infection.

Authors:  Joachim Richter; Ingrid Hanus; Dieter Häussinger; Thomas Löscher; Gundel Harms
Journal:  Parasitol Res       Date:  2011-04-16       Impact factor: 2.289

2.  Evaluation of a hypothetical protein for serodiagnosis and as a potential marker for post-treatment serological evaluation of tegumentary leishmaniasis patients.

Authors:  Mariana Pedrosa Lima; Lourena Emanuele Costa; Mariana Costa Duarte; Daniel Menezes-Souza; Beatriz Cristina Silveira Salles; Thaís Teodoro de Oliveira Santos; Fernanda Fonseca Ramos; Miguel Angel Chávez-Fumagalli; Amanda Christine Silva Kursancew; Roberta Passamani Ambrósio; Bruno Mendes Roatt; Ricardo Andrez Machado-de-Ávila; Denise Utsch Gonçalves; Eduardo Antonio Ferraz Coelho
Journal:  Parasitol Res       Date:  2017-02-01       Impact factor: 2.289

3.  Diagnosing Cutaneous leishmaniasis using Fluorescence in Situ Hybridization: the Sri Lankan Perspective.

Authors:  Thilini Dilhara Jayasena Kaluarachchi; Manjula Manoji Weerasekera; Andrew J McBain; Shalindra Ranasinghe; Renu Wickremasinghe; Surangi Yasawardene; Nisal Jayanetti; Rajitha Wickremasinghe
Journal:  Pathog Glob Health       Date:  2019-08-20       Impact factor: 2.894

4.  Leprosy Associated with Atypical Cutaneous Leishmaniasis in Nicaragua and Honduras.

Authors:  Lucrecia Acosta Soto; Nelson Caballero; Lesny Ruth Fuentes; Pedro Torres Muñoz; Jose Ramón Gómez Echevarría; Montserrat Pérez López; Fernando Jorge Bornay Llinares; John L Stanford; Cynthia A Stanford; Helen D Donoghue
Journal:  Am J Trop Med Hyg       Date:  2017-10       Impact factor: 2.345

5.  Serodiagnosis of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica in Sanliurfa Province, Turkey, where ACL Is highly endemic.

Authors:  Fadile Yildiz Zeyrek; Metin Korkmaz; Yusuf Ozbel
Journal:  Clin Vaccine Immunol       Date:  2007-08-29

6.  Specific K39 antibody response and its persistence after treatment in patients with imported leishmaniasis.

Authors:  Ingrid Reiter-Owona; Claudia Rehkaemper-Schaefer; Sandra Arriens; Philip Rosenstock; Kenneth Pfarr; Achim Hoerauf
Journal:  Parasitol Res       Date:  2015-10-28       Impact factor: 2.289

7.  Design and characterization of high-affinity synthetic peptides as bioreceptors for diagnosis of cutaneous leishmaniasis.

Authors:  Y Andrea Prada; Maria Soler; Fanny Guzmán; John J Castillo; Laura M Lechuga; Enrique Mejía-Ospino
Journal:  Anal Bioanal Chem       Date:  2021-05-26       Impact factor: 4.142

8.  Characterization of Leishmania spp. causing cutaneous leishmaniasis in Manaus, Amazonas, Brazil.

Authors:  Leila Ines Camara Coelho; Marcilene Paes; Jorge Augusto Guerra; Maria das Graças Barbosa; Candisse Coelho; Bruna Lima; Maria Edileuza Brito; Sinval Pinto Brandão Filho
Journal:  Parasitol Res       Date:  2010-11-12       Impact factor: 2.289

9.  Towards a more precise serological diagnosis of human tegumentary leishmaniasis using Leishmania recombinant proteins.

Authors:  Ana Paula Souza; Manuel Soto; Jackson M L Costa; Viviane S Boaventura; Camila I de Oliveira; Juqueline R Cristal; Manoel Barral-Netto; Aldina Barral
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

10.  Interventions for American cutaneous and mucocutaneous leishmaniasis.

Authors:  Mariona Pinart; José-Ramón Rueda; Gustavo As Romero; Carlos Eduardo Pinzón-Flórez; Karime Osorio-Arango; Ana Nilce Silveira Maia-Elkhoury; Ludovic Reveiz; Vanessa M Elias; John A Tweed
Journal:  Cochrane Database Syst Rev       Date:  2020-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.